On the public citation graph

An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study

0 signed · 19 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.20866openalex-extracted

Incidence of noncutaneous melanomas in the U.S.

inferredcites →https://doi.org/10.1002/cncr.23086openalex-extracted

Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

inferredcites →https://doi.org/10.1007/s10637-016-0373-4openalex-extracted

Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry

inferredcites →https://doi.org/10.1016/j.jaad.2008.11.582openalex-extracted

Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2004

inferredcites →https://doi.org/10.1016/s0093-3619(09)79459-6openalex-extracted

Acral Lentiginous Melanoma: Incidence and Survival Patterns in the United States, 1986-2005

inferredcites →https://doi.org/10.1016/s2352-3026(18)30192-3openalex-extracted

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

inferredcites →https://doi.org/10.1038/bjc.2013.227openalex-extracted

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-extracted

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1414428openalex-extracted

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-extracted

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1910836openalex-extracted

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

inferredcites →https://doi.org/10.1080/19420862.2019.1654303openalex-extracted

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

inferredcites →https://doi.org/10.1126/science.1253735openalex-extracted

The melanoma revolution: From UV carcinogenesis to a new era in therapeutics

inferredcites →https://doi.org/10.1136/jitc-2021-003318openalex-extracted

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial

inferredcites →https://doi.org/10.1186/1471-2407-11-85openalex-extracted

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

inferredcites →https://doi.org/10.1200/jco.2005.01.109openalex-extracted

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

inferredcites →https://doi.org/10.1200/jco.2008.17.8954openalex-extracted

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

inferredcites →https://doi.org/10.21037/cco.2015.12.02openalex-extracted

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)

inferredcites →https://doi.org/10.3978/j.issn.2305-5839.2015.12.23openalex-extracted

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.